WallStSmart

Novartis AG ADR (NVS)vsTactile Systems Technology Inc (TCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 17070% more annual revenue ($56.58B vs $329.52M). NVS leads profitability with a 23.9% profit margin vs 5.8%. NVS appears more attractively valued with a PEG of 2.48. TCMD earns a higher WallStSmart Score of 58/100 (C).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

TCMD

Buy

58

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 6.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued
TCMDUndervalued (+55.5%)

Margin of Safety

+55.5%

Fair Value

$62.14

Current Price

$22.50

$39.64 discount

UndervaluedFair: $62.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

TCMD2 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

TCMD4 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$536.23M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

PEG RatioValuation
17.792/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : TCMD

The strongest argument for TCMD centers on Price/Book, Revenue Growth. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : TCMD

The primary concerns for TCMD are P/E Ratio, Market Cap, Profit Margin.

Key Dynamics to Monitor

NVS profiles as a declining stock while TCMD is a growth play — different risk/reward profiles.

TCMD carries more volatility with a beta of 0.99 — expect wider price swings.

TCMD is growing revenue faster at 21.0% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

TCMD scores higher overall (58/100 vs 51/100) and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Tactile Systems Technology Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.

Want to dig deeper into these stocks?